TCG Crossover Management’s Tourmaline Bio TRML Stock Holding History

TCG Crossover Management’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,311,783	Closed	-$62.7M	–	48
2025 Q3	$62.7M	Sell	1,311,783 -165,810	-11%	-$4.6M	3.09%	9
2025 Q2	$23.6M	Hold	1,477,593	–	–	2.7%	17
2025 Q1	$22.5M	Hold	1,477,593	–	–	3.07%	13
2024 Q4	$30M	Hold	1,477,593	–	–	2.93%	14
2024 Q3	$38M	Hold	1,477,593	–	–	3.22%	14
2024 Q2	$19M	Hold	1,477,593	–	–	1.98%	20
2024 Q1	$33.8M	Buy	1,477,593 +469,691	+47%	+$16.6M	2.68%	16
2023 Q4	$26.4M	Buy	+1,007,902	New	+$20.2M	2.93%	16

TCG Crossover Management's TRML Position: Q4 2025 in Review

TCG Crossover Management sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 1,311,783 shares — an estimated $62.7M sold.

TCG Crossover Management first reported a position in TRML in Q4 2023 and held it in 8 quarters. The position peaked at $62.7M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

TCG Crossover Management reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
TCG Crossover Management sold 1,311,783 Tourmaline Bio shares in Q4 2025, an estimated $62.7M.
TCG Crossover Management first reported a position in Tourmaline Bio in Q4 2023 and held it in 8 quarters.
TCG Crossover Management's Tourmaline Bio position peaked at $62.7M in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on TCG Crossover Management's 13F filing for Q4 2025, filed 17 Feb 2026.